Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea
The Korea Centers for Disease Control & Prevention has implemented a review process for the approval of new drugs used to treat patients with multidrug-resistant tuberculosis (MDR-TB) since September 2016. Therefore, this study aimed to evaluate the efficacy and safety of these new drugs bedaqui...
Gespeichert in:
| Veröffentlicht in: | Respiratory medicine 2020-06, Vol.167, p.105956-105956, Article 105956 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 105956 |
|---|---|
| container_issue | |
| container_start_page | 105956 |
| container_title | Respiratory medicine |
| container_volume | 167 |
| creator | Kang, Hyungseok Jo, Kyung-Wook Jeon, Doosoo Yim, Jae-Joon Shim, Tae Sun |
| description | The Korea Centers for Disease Control & Prevention has implemented a review process for the approval of new drugs used to treat patients with multidrug-resistant tuberculosis (MDR-TB) since September 2016. Therefore, this study aimed to evaluate the efficacy and safety of these new drugs bedaquiline (Bdq) and delamanid (Dlm).
A total of 318 patients with MDR-TB were reviewed by the committee from September 2016 to February 2018; 282 (88.7%) of them were treated with the new drugs (Bdq, 107 patients; Dlm, 108 patients; and both concurrently or sequentially, 67 patients) and retrospectively evaluated. Culture conversion rates, interim treatment outcomes at 12 months, and predictors of unfavorable outcomes were analyzed. Treatment efficacy was also compared between Bdq and Dlm.
The mean age of the patients was 49.3 years, and 197 (69.9%) were male. Three patients were HIV seropositive and 151 (53.5%) were quinolone resistant. The culture conversion rates at 2 and 6 months were 57.4% (81/141) and 89.4% (126/141), respectively. A favorable outcome at 12 months was achieved in 84.8% of patients (239/282). Differences in the culture conversion rate or interim treatment outcomes were not statistically significant among the drug susceptibility test patterns or new drugs used. Multivariable analysis showed that age >60 years and body mass index of |
| doi_str_mv | 10.1016/j.rmed.2020.105956 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2404639378</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0954611120300962</els_id><sourcerecordid>2425693346</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-e40dbe5325d7090c95dbda7180e2ccb2c0757256bd106c56f1a6da5f08c1ee13</originalsourceid><addsrcrecordid>eNp9kT1vFDEQhi0EIsfBH6BAlmho9jL22t5biQZFfEREoiC95bXngk-79sUfkfj3eHVJQ5HK0swz74zfl5D3DHYMmLo87tKCbseBrwU5SvWCbJjsedeDEi_JBkYpOsUYuyBvcj4CwCgEvCYXPRecSQEbcroOBZNfaEloyoKh0FiLjQtm6gNd6ly8S_WuS5h9Lqb1S50w2TrHVqA1-3BHJ3TmvvrZB6QmuMuYqMPZLCZ4t8r8bpp_6M_Ydrwlrw5mzvju8d2S229fb69-dDe_vl9ffbnprOD70qEAN2H7i3QDjGBH6SZnBrYH5NZO3MIgBy7V5BgoK9WBGeWMPMDeMkTWb8mns-wpxfuKuejFZ4vzbALGmjUXIFQ_9sO-oR__Q4-xptCOa1RbMfZ9Q7eEnymbYs4JD_rUbDPpr2ag1zj0Ua9x6DUOfY6jDX14lK7T2nsaefK_AZ_PADYrHjwmna3HYNH5hLZoF_1z-v8AZq-dFw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425693346</pqid></control><display><type>article</type><title>Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kang, Hyungseok ; Jo, Kyung-Wook ; Jeon, Doosoo ; Yim, Jae-Joon ; Shim, Tae Sun</creator><creatorcontrib>Kang, Hyungseok ; Jo, Kyung-Wook ; Jeon, Doosoo ; Yim, Jae-Joon ; Shim, Tae Sun</creatorcontrib><description>The Korea Centers for Disease Control & Prevention has implemented a review process for the approval of new drugs used to treat patients with multidrug-resistant tuberculosis (MDR-TB) since September 2016. Therefore, this study aimed to evaluate the efficacy and safety of these new drugs bedaquiline (Bdq) and delamanid (Dlm).
A total of 318 patients with MDR-TB were reviewed by the committee from September 2016 to February 2018; 282 (88.7%) of them were treated with the new drugs (Bdq, 107 patients; Dlm, 108 patients; and both concurrently or sequentially, 67 patients) and retrospectively evaluated. Culture conversion rates, interim treatment outcomes at 12 months, and predictors of unfavorable outcomes were analyzed. Treatment efficacy was also compared between Bdq and Dlm.
The mean age of the patients was 49.3 years, and 197 (69.9%) were male. Three patients were HIV seropositive and 151 (53.5%) were quinolone resistant. The culture conversion rates at 2 and 6 months were 57.4% (81/141) and 89.4% (126/141), respectively. A favorable outcome at 12 months was achieved in 84.8% of patients (239/282). Differences in the culture conversion rate or interim treatment outcomes were not statistically significant among the drug susceptibility test patterns or new drugs used. Multivariable analysis showed that age >60 years and body mass index of <18.5 kg/m2 were significant risk factors for unfavorable outcomes at 12 months.
The use of new drugs resulted in satisfactory interim treatment results, without significant differences between them.
•Bdq and/or Dlm-containing regimen achieved satisfactory interim treatment outcomes.•The efficacy of Bdq and Dlm seemed to be similar.•Adverse drug reactions of two drugs very rarely occurred.</description><identifier>ISSN: 0954-6111</identifier><identifier>EISSN: 1532-3064</identifier><identifier>DOI: 10.1016/j.rmed.2020.105956</identifier><identifier>PMID: 32421540</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Bedaquiline ; Body mass ; Body mass index ; Body size ; Clinical outcomes ; Conversion ; Delamanid ; Disease control ; Drug resistance ; Drugs ; FDA approval ; Health insurance ; HIV ; Human immunodeficiency virus ; Multidrug resistance ; Multidrug resistant organisms ; Multidrug-resistant tuberculosis ; Patients ; Risk analysis ; Risk factors ; South Korea ; Statistical analysis ; Tuberculosis</subject><ispartof>Respiratory medicine, 2020-06, Vol.167, p.105956-105956, Article 105956</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-e40dbe5325d7090c95dbda7180e2ccb2c0757256bd106c56f1a6da5f08c1ee13</citedby><cites>FETCH-LOGICAL-c428t-e40dbe5325d7090c95dbda7180e2ccb2c0757256bd106c56f1a6da5f08c1ee13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0954611120300962$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32421540$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Hyungseok</creatorcontrib><creatorcontrib>Jo, Kyung-Wook</creatorcontrib><creatorcontrib>Jeon, Doosoo</creatorcontrib><creatorcontrib>Yim, Jae-Joon</creatorcontrib><creatorcontrib>Shim, Tae Sun</creatorcontrib><title>Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea</title><title>Respiratory medicine</title><addtitle>Respir Med</addtitle><description>The Korea Centers for Disease Control & Prevention has implemented a review process for the approval of new drugs used to treat patients with multidrug-resistant tuberculosis (MDR-TB) since September 2016. Therefore, this study aimed to evaluate the efficacy and safety of these new drugs bedaquiline (Bdq) and delamanid (Dlm).
A total of 318 patients with MDR-TB were reviewed by the committee from September 2016 to February 2018; 282 (88.7%) of them were treated with the new drugs (Bdq, 107 patients; Dlm, 108 patients; and both concurrently or sequentially, 67 patients) and retrospectively evaluated. Culture conversion rates, interim treatment outcomes at 12 months, and predictors of unfavorable outcomes were analyzed. Treatment efficacy was also compared between Bdq and Dlm.
The mean age of the patients was 49.3 years, and 197 (69.9%) were male. Three patients were HIV seropositive and 151 (53.5%) were quinolone resistant. The culture conversion rates at 2 and 6 months were 57.4% (81/141) and 89.4% (126/141), respectively. A favorable outcome at 12 months was achieved in 84.8% of patients (239/282). Differences in the culture conversion rate or interim treatment outcomes were not statistically significant among the drug susceptibility test patterns or new drugs used. Multivariable analysis showed that age >60 years and body mass index of <18.5 kg/m2 were significant risk factors for unfavorable outcomes at 12 months.
The use of new drugs resulted in satisfactory interim treatment results, without significant differences between them.
•Bdq and/or Dlm-containing regimen achieved satisfactory interim treatment outcomes.•The efficacy of Bdq and Dlm seemed to be similar.•Adverse drug reactions of two drugs very rarely occurred.</description><subject>Bedaquiline</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Clinical outcomes</subject><subject>Conversion</subject><subject>Delamanid</subject><subject>Disease control</subject><subject>Drug resistance</subject><subject>Drugs</subject><subject>FDA approval</subject><subject>Health insurance</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Multidrug resistance</subject><subject>Multidrug resistant organisms</subject><subject>Multidrug-resistant tuberculosis</subject><subject>Patients</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>South Korea</subject><subject>Statistical analysis</subject><subject>Tuberculosis</subject><issn>0954-6111</issn><issn>1532-3064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kT1vFDEQhi0EIsfBH6BAlmho9jL22t5biQZFfEREoiC95bXngk-79sUfkfj3eHVJQ5HK0swz74zfl5D3DHYMmLo87tKCbseBrwU5SvWCbJjsedeDEi_JBkYpOsUYuyBvcj4CwCgEvCYXPRecSQEbcroOBZNfaEloyoKh0FiLjQtm6gNd6ly8S_WuS5h9Lqb1S50w2TrHVqA1-3BHJ3TmvvrZB6QmuMuYqMPZLCZ4t8r8bpp_6M_Ydrwlrw5mzvju8d2S229fb69-dDe_vl9ffbnprOD70qEAN2H7i3QDjGBH6SZnBrYH5NZO3MIgBy7V5BgoK9WBGeWMPMDeMkTWb8mns-wpxfuKuejFZ4vzbALGmjUXIFQ_9sO-oR__Q4-xptCOa1RbMfZ9Q7eEnymbYs4JD_rUbDPpr2ag1zj0Ua9x6DUOfY6jDX14lK7T2nsaefK_AZ_PADYrHjwmna3HYNH5hLZoF_1z-v8AZq-dFw</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Kang, Hyungseok</creator><creator>Jo, Kyung-Wook</creator><creator>Jeon, Doosoo</creator><creator>Yim, Jae-Joon</creator><creator>Shim, Tae Sun</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>ASE</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>202006</creationdate><title>Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea</title><author>Kang, Hyungseok ; Jo, Kyung-Wook ; Jeon, Doosoo ; Yim, Jae-Joon ; Shim, Tae Sun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-e40dbe5325d7090c95dbda7180e2ccb2c0757256bd106c56f1a6da5f08c1ee13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Bedaquiline</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Clinical outcomes</topic><topic>Conversion</topic><topic>Delamanid</topic><topic>Disease control</topic><topic>Drug resistance</topic><topic>Drugs</topic><topic>FDA approval</topic><topic>Health insurance</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Multidrug resistance</topic><topic>Multidrug resistant organisms</topic><topic>Multidrug-resistant tuberculosis</topic><topic>Patients</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>South Korea</topic><topic>Statistical analysis</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Hyungseok</creatorcontrib><creatorcontrib>Jo, Kyung-Wook</creatorcontrib><creatorcontrib>Jeon, Doosoo</creatorcontrib><creatorcontrib>Yim, Jae-Joon</creatorcontrib><creatorcontrib>Shim, Tae Sun</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Hyungseok</au><au>Jo, Kyung-Wook</au><au>Jeon, Doosoo</au><au>Yim, Jae-Joon</au><au>Shim, Tae Sun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea</atitle><jtitle>Respiratory medicine</jtitle><addtitle>Respir Med</addtitle><date>2020-06</date><risdate>2020</risdate><volume>167</volume><spage>105956</spage><epage>105956</epage><pages>105956-105956</pages><artnum>105956</artnum><issn>0954-6111</issn><eissn>1532-3064</eissn><abstract>The Korea Centers for Disease Control & Prevention has implemented a review process for the approval of new drugs used to treat patients with multidrug-resistant tuberculosis (MDR-TB) since September 2016. Therefore, this study aimed to evaluate the efficacy and safety of these new drugs bedaquiline (Bdq) and delamanid (Dlm).
A total of 318 patients with MDR-TB were reviewed by the committee from September 2016 to February 2018; 282 (88.7%) of them were treated with the new drugs (Bdq, 107 patients; Dlm, 108 patients; and both concurrently or sequentially, 67 patients) and retrospectively evaluated. Culture conversion rates, interim treatment outcomes at 12 months, and predictors of unfavorable outcomes were analyzed. Treatment efficacy was also compared between Bdq and Dlm.
The mean age of the patients was 49.3 years, and 197 (69.9%) were male. Three patients were HIV seropositive and 151 (53.5%) were quinolone resistant. The culture conversion rates at 2 and 6 months were 57.4% (81/141) and 89.4% (126/141), respectively. A favorable outcome at 12 months was achieved in 84.8% of patients (239/282). Differences in the culture conversion rate or interim treatment outcomes were not statistically significant among the drug susceptibility test patterns or new drugs used. Multivariable analysis showed that age >60 years and body mass index of <18.5 kg/m2 were significant risk factors for unfavorable outcomes at 12 months.
The use of new drugs resulted in satisfactory interim treatment results, without significant differences between them.
•Bdq and/or Dlm-containing regimen achieved satisfactory interim treatment outcomes.•The efficacy of Bdq and Dlm seemed to be similar.•Adverse drug reactions of two drugs very rarely occurred.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32421540</pmid><doi>10.1016/j.rmed.2020.105956</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6111 |
| ispartof | Respiratory medicine, 2020-06, Vol.167, p.105956-105956, Article 105956 |
| issn | 0954-6111 1532-3064 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2404639378 |
| source | Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Bedaquiline Body mass Body mass index Body size Clinical outcomes Conversion Delamanid Disease control Drug resistance Drugs FDA approval Health insurance HIV Human immunodeficiency virus Multidrug resistance Multidrug resistant organisms Multidrug-resistant tuberculosis Patients Risk analysis Risk factors South Korea Statistical analysis Tuberculosis |
| title | Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T11%3A14%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interim%20treatment%20outcomes%20in%20multidrug-resistant%20tuberculosis%20using%20bedaquiline%20and/or%20delamanid%20in%20South%20Korea&rft.jtitle=Respiratory%20medicine&rft.au=Kang,%20Hyungseok&rft.date=2020-06&rft.volume=167&rft.spage=105956&rft.epage=105956&rft.pages=105956-105956&rft.artnum=105956&rft.issn=0954-6111&rft.eissn=1532-3064&rft_id=info:doi/10.1016/j.rmed.2020.105956&rft_dat=%3Cproquest_cross%3E2425693346%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425693346&rft_id=info:pmid/32421540&rft_els_id=S0954611120300962&rfr_iscdi=true |